Eczema (Atopic Dermatitis) Clinical Trial

Eczema Clinical Trial for ANB032

Testing a cutting-edge, injectable Eczema treatment for safety and effectiveness

Welcome to our clinical research trial page for the study of ANB203 for Atopic Dermatitis (AD), or Eczema.

ANB203 is a new injectable biologic drug that has been chosen for research in its potential for turning off symptoms of Eczema in the body.

This novel form of treatment can be much more effective than topicals or creams for Eczema because it targets the underlying cause of symptoms.

Requirements

18-65 years of age.
At least 6 months of moderate or severe Eczema,
affecting at least 10% of the skin’s surface.
A history of inadequate response to topical medications.

Volunteers will be paid for time and expenses.

The trial will last 7-8 months and require around 12 visits to the study centre.

First Name

Last Name

Phone Number

Email Address

Postal Code

Sex

Best Contact Method

Email SMS Text Home Phone Cell Phone

Best Time to Reach You

Morning (8 – 11AM) Lunchtime (11AM – 1PM) Afternoon (1 – 5PM) Evening (After 5PM)

How Did You Hear About Us?

Please check the box to confirm you meet the study requirements, and consent to: (1) sharing your information with the study site, and (2) our Privacy Policy (click 'Privacy Policy' to review). By checking this box, you also agree to receive study-related text notifications. You can opt out at any time. Message and data rates may apply. T-mobile is not responsible for message delays. For assistance, text HELP, and to unsubscribe, text STOP. All provided information is confidential and will not be shared without your consent.

Confirm